European urology最新文献

{"title":"Integrating Pathogenic Variants, Polygenic Risk Score, and Family History for Prostate Cancer Risk Estimation in Men of African Ancestry","authors":"Fei Chen ,&nbsp;Xin Sheng ,&nbsp;Anqi Wang ,&nbsp;Yili Xu ,&nbsp;Raymond Hughley ,&nbsp;Wei Xiong ,&nbsp;Loreall Pooler ,&nbsp;Peggy Wan ,&nbsp;Susan M. Gundell ,&nbsp;Godfrey Kigozi ,&nbsp;Gertrude Nakigozi ,&nbsp;Fred Nalugoda ,&nbsp;Joseph Kagaayi ,&nbsp;Grace Nalwoga Kigozi ,&nbsp;Stephen Mugamba ,&nbsp;Emmanuel Kyasanku ,&nbsp;James Nkale ,&nbsp;Vitalis Ofumbi Olwa ,&nbsp;Alexander Lubwama ,&nbsp;Alex Daama ,&nbsp;Christopher A. Haiman","doi":"10.1016/j.eururo.2025.09.4161","DOIUrl":"10.1016/j.eururo.2025.09.4161","url":null,"abstract":"<div><h3>Background and objective</h3><div>The impact of germline pathogenic variants (PVs) in cancer predisposition genes on risk of prostate cancer (PCa) remains understudied in large populations of African ancestry. This study aims to characterize the range of genetic risk of PCa and aggressive disease phenotypes in men of African ancestry.</div></div><div><h3>Methods</h3><div>We analyzed 7176 PCa cases and 4873 controls from seven countries across North America and Africa to assess the association between PVs in 37 cancer predisposition genes and the risk of overall, aggressive, and metastatic PCa. Genes significantly associated with PCa risk were used to estimate lifetime absolute risk based on family history, polygenic risk score (PRS), and PV carrier status.</div></div><div><h3>Key findings and limitations</h3><div>PVs in <em>ATM</em>, <em>BRCA2</em>, <em>CHEK2</em>, <em>HOXB13</em>, and <em>PALB2</em> were presented in 4% of aggressive/metastatic PCa cases and were significantly associated with an increased risk of aggressive PCa (odds ratio 2.18–5.96, <em>p</em> &lt; 0.05). Lifetime absolute risk varied widely depending on PV carrier status, PRS, and family history, ranging from 3.0% to 74% for overall PCa, 0.6% to 41% for aggressive PCa, and 0.2% to 37% for metastatic PCa. PV carriers with a positive family history and a PRS in the 90th percentile had seven, 18, and 34 times the risks of overall, aggressive, and metastatic PCa, respectively, compared with average-risk individuals. Oversampling of aggressive cases may limit the generalizability of these findings to screening populations.</div></div><div><h3>Conclusions and clinical implications</h3><div>Integration of PV status, PRS, and family history enables more refined PCa risk estimates. The wide range of PCa risk observed among men of African ancestry in our study supports future prospective studies in the development of risk-stratified cancer screening programs to identify high-risk individuals who may benefit from screening at an earlier age.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Pages 416-425"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145485695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study","authors":"Elizabeth K. Bancroft ,&nbsp;Elizabeth C. Page ,&nbsp;Jana McHugh ,&nbsp;Sarah Thomas ,&nbsp;Natalie Taylor ,&nbsp;Jennifer Pope ,&nbsp;D.Gareth Evans ,&nbsp;Jeanette Rothwell ,&nbsp;Eli Marie Grindedal ,&nbsp;Lovise Maehle ,&nbsp;Paul James ,&nbsp;Joanne McKinley ,&nbsp;Lyon Mascarenhas ,&nbsp;Lucy Side ,&nbsp;Tessy Thomas ,&nbsp;Monique E. van Leerdam ,&nbsp;Christi J. van Asperen ,&nbsp;Lambertus A.L.M. Kiemeney ,&nbsp;Janneke Ringelberg ,&nbsp;Michiel Vlaming ,&nbsp;Rosalind A. Eeles","doi":"10.1016/j.eururo.2026.01.031","DOIUrl":"10.1016/j.eururo.2026.01.031","url":null,"abstract":"<div><h3>Background and objective</h3><div><em>BRCA1</em> and <em>BRCA2</em> pathogenic germline variants (PGVs) are associated with higher risk of prostate cancer (PC). The IMPACT study evaluated the utility of targeted prostate-specific antigen (PSA) screening in <em>BRCA1</em>/<em>BRCA2</em> PGV carriers. Here we report outcomes after five rounds of PSA screening in IMPACT.</div></div><div><h3>Methods</h3><div>Between 2005 and 2015, 3063 participants aged 40–69 yr (median 54 yr) were recruited from 65 centres in 20 countries in two cohorts: (1) <em>BRCA1</em>/<em>BRCA2</em> PGV carriers (915 <em>BRCA1</em>, 901 <em>BRCA2</em>); and (2) age-matched noncarriers for a familial PGV (727 <em>BRCA1</em> and 520 <em>BRCA2</em> noncarriers). Annual PSA screening was performed, with PSA &gt;3.0 ng/ml used as the indication for prostate biopsy. Our aim was to identify differences by PGV status in (1) the incidence of PC and of clinically significant PC (csPC; grade group ≥2) and (2) tumour stage and characteristics after five screening rounds.</div></div><div><h3>Key findings and limitations</h3><div>There was no statistically significant difference in PC incidence between <em>BRCA1/BRCA2</em> PGV carriers and noncarriers. csPC incidence was significantly higher for <em>BRCA2</em> PGV carriers than for noncarriers (3.1% vs 1.3%; <em>p</em> = 0.04). Among men with PC, the proportion of tumours with National Comprehensive Cancer Network intermediate unfavourable/high risk was higher in the <em>BRCA1</em>/<em>BRCA2</em> PGV groups versus the corresponding group without PGVs <em>(BRCA2</em>: 65% vs 32%, <em>p</em> = 0.029; <em>BRCA1</em>: 56% vs 18%, <em>p</em> = 0.0017). There were no T4 or metastatic PC cases. Pathology after radical prostatectomy revealed tumour upgrading for 7/23 (26%) <em>BRCA1</em> PGV carriers and 10/34 (26%) <em>BRCA2</em> PGV carriers, with no tumour upgrading for men without PGVs. Study limitations include the biopsy compliance rate and changes in PC diagnostic pathways since 2005.</div></div><div><h3>Conclusions and clinical implications</h3><div>Annual PSA screening in <em>BRCA2</em> PGV carriers confirmed a higher incidence of csPC and detection of clinically relevant tumours in comparison to noncarriers. For the first time, we confirm that PSA screening in <em>BRCA1</em> PGV carriers results in early detection of NCCN IR-U/HR PC. Systematic PSA screening is recommended for <em>BRCA2</em> PGV carriers and should be considered for <em>BRCA1</em> PGV carriers.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Pages 457-468"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146230389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212–4","authors":"Jorge Esteban-Villarrubia,&nbsp;Guillermo de Velasco","doi":"10.1016/j.eururo.2025.11.022","DOIUrl":"10.1016/j.eururo.2025.11.022","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Page e120"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145770445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Jorge Esteban-Villarrubia and Guillermo De Velasco’s Letter to the Editor re: Daniel S. Roberson, Vidit Sharma, Stephen A. Boorjian, et al. Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis. Eur Urol 2025;88:212–4","authors":"Daniel S. Roberson,&nbsp;Abhinav Khanna","doi":"10.1016/j.eururo.2025.11.017","DOIUrl":"10.1016/j.eururo.2025.11.017","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Page e119"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends","authors":"Adalberto M. Filho ,&nbsp;Alberto Briganti ,&nbsp;Ahmedin Jemal ,&nbsp;Freddie Bray","doi":"10.1016/j.eururo.2025.12.011","DOIUrl":"10.1016/j.eururo.2025.12.011","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background and objective&lt;/h3&gt;&lt;div&gt;Bladder cancer is the most common tumor of the urinary tract and the ninth most common cancer worldwide. Our objective was to describe and interpret current geographic variations in bladder cancer incidence and mortality rates using updated national estimates and recorded data from population-based cancer registries alongside national vital statistics.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;The bladder cancer incidence and mortality for 185 countries by sex were obtained from GLOBOCAN (International Agency for Research on Cancer) for the year 2022. Recorded incidence and mortality data were retrieved from national or subnational population-based cancer registries included in the &lt;em&gt;Cancer Incidence in Five Continents&lt;/em&gt; series and the World Health Organization database, respectively. Corresponding age-standardized rates (ASRs) per 100000 person-years were calculated using direct standardization (world standard), and temporal trends of ASRs by calendar period and sex are presented by country, with the direction and magnitude of recent trends quantified using the estimated annual percentage change (EAPC).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Key findings and limitations&lt;/h3&gt;&lt;div&gt;In 2022, an estimated 614298 new cases of bladder cancer and 220596 deaths occurred worldwide, with approximately 75% of the burden observed in males. Urothelial and squamous cell carcinomas were the predominant histological subtypes across all regions. Incidence and mortality rates varied substantially across regions and countries, with the highest rates reported in Europe, particularly in southern (ASR: 28.7) and northern (20.4) regions, and elevated rates were also seen in North America (18.0), Northern Africa (16.3), and Western Asia (15.2). Despite lower age-standardized rates, Eastern Asia reported the highest absolute numbers due to its large population. Temporal trends indicate a stabilizing or declining incidence in many high-income countries. Mortality rates have overall declined across many populations, for example, in Australia (EAPC in male: −2.6; female: −2.3), the Netherlands (male: 2.9; female: −1.6), and the USA (male: −1.3; female: −1.0). Interpretation of bladder cancer incidence patterns and trends requires caution given possible variations in cancer registration practice, notably as to whether noninvasive tumors are included in reporting.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions and clinical implications&lt;/h3&gt;&lt;div&gt;Bladder cancer continues to pose a significant global health challenge, with marked geographic and sex-based disparities in the incidence and mortality. While encouraging declines in rates are observed in many high-income countries, the burden remains substantial in these regions and rates are rising in some settings. Tobacco smoking remains the predominant risk factor, with historical and current prevalence patterns aligned closely with disease trends. However, in Northern Africa, schistosomiasis contributes to an elevated in","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Pages 426-436"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145784518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: ACOX2 Destabilizes the MRE11-RAD50-NBS1 Complex and Boosts Anticancer Immunity via the cGAS-STING Pathway in Clear Cell Renal Cell Carcinoma","authors":"Hangbiao Zhang ,&nbsp;Yifan Liu ,&nbsp;Jialin Zhou ,&nbsp;Bingnan Lu ,&nbsp;Yuntao Yao ,&nbsp;Yuanbo Zong ,&nbsp;Xingang Cui,&nbsp;Xiuwu Pan","doi":"10.1016/j.eururo.2025.12.026","DOIUrl":"10.1016/j.eururo.2025.12.026","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Pages 472-473"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145937951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Nikita Bhatt, Benoit Peyronnet, and Lee Zhao’s Letter to the Editor re: Matthew Lee, Michael Lesgart, Connor McPartland, Randall Lee, Daniel D. Eun. Robotic Transvesical Bladder Neck Reconstruction: A Novel Approach to Managing Vesicourethral Anastomotic Stenosis. Eur Urol. 2025;88:519–24","authors":"Matthew Lee,&nbsp;Daniel D. Eun","doi":"10.1016/j.eururo.2025.12.016","DOIUrl":"10.1016/j.eururo.2025.12.016","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Pages e123-e124"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145822524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients","authors":"Andrew J. Armstrong ,&nbsp;Daniel P. Petrylak ,&nbsp;Neal D. Shore ,&nbsp;Russell Z. Szmulewitz ,&nbsp;Jeffrey Holzbeierlein ,&nbsp;Arnauld Villers ,&nbsp;Antonio Alcaraz ,&nbsp;Boris Alekseev ,&nbsp;Taro Iguchi ,&nbsp;Francisco Gomez-Veiga ,&nbsp;Ruslan Croitoru ,&nbsp;Ruishan Wu ,&nbsp;Matko Kalac ,&nbsp;Yiyun Tang ,&nbsp;Arnulf Stenzl ,&nbsp;Arun A. Azad","doi":"10.1016/j.eururo.2025.12.021","DOIUrl":"10.1016/j.eururo.2025.12.021","url":null,"abstract":"<div><div>The ARCHES trial (NCT02677896) showed improved radiographic progression-free survival (primary analysis; 2018) and overall survival (prespecified analysis; 2021) with enzalutamide versus placebo, with concomitant androgen-deprivation therapy, in metastatic hormone-sensitive prostate cancer (mHSPC) patients. This post hoc analysis describes 5-yr efficacy and safety for all 1150 randomized patients (data cutoff: July 31, 2024). Patients were randomized 1:1 to receive enzalutamide or placebo (first patient randomized: March 21, 2016). After the primary analysis, ARCHES was unblinded (December 10, 2018); 65% and 32% of patients in the enzalutamide and placebo groups, respectively, enrolled in the open-label extension. After the 61.4-mo median follow-up, 5-yr survival probability was 66% with enzalutamide and 53% with placebo (median months not reached in either group; hazard ratio [HR]: 0.70; 95% confidence interval [CI]: 0.58, 0.85; <em>p</em> &lt; 0.001; adjusted HR: 0.64; 95% CI: 0.51, 0.75). Patients with high-volume disease who received enzalutamide lived 36 mo longer than those who received placebo (HR: 0.70; 95% CI: 0.56, 0.88). No new safety signals emerged. As this was a post hoc, non–alpha protected analysis, the overall survival <em>p</em> value is nominal and should be interpreted cautiously. Overall, this study provides compelling long-term data demonstrating survival benefits with enzalutamide across diverse patient subgroups to guide clinical decision-making and establish prognostic expectations in the mHSPC setting.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Pages 396-403"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146101577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial","authors":"Hiroshi Kitamura ,&nbsp;Taiji Tsukamoto ,&nbsp;Yoshiyuki Kakehi ,&nbsp;Junki Mizusawa ,&nbsp;Taro Shibata ,&nbsp;Keita Sasaki ,&nbsp;Toshiki Tanikawa ,&nbsp;Katsuyoshi Hashine ,&nbsp;Kiyohide Fujimoto ,&nbsp;Naoya Masumori ,&nbsp;Takashi Kobayashi ,&nbsp;Tomonori Habuchi ,&nbsp;Takahiro Kimura ,&nbsp;Mikio Sugimoto ,&nbsp;Atsushi Takahashi ,&nbsp;Hisanobu Adachi ,&nbsp;Yoshiyuki Matsui ,&nbsp;Shingo Hatakeyama ,&nbsp;Akihiro Ito ,&nbsp;Masatoshi Eto ,&nbsp;Hiroyuki Nishiyama","doi":"10.1016/j.eururo.2026.01.008","DOIUrl":"10.1016/j.eururo.2026.01.008","url":null,"abstract":"<div><h3>Background and objective</h3><div>We evaluated the noninferiority of active surveillance (AS) in comparison to intravesical bacillus Calmette-Guérin (BCG) in terms of recurrence and progression for patients with high-grade T1 (HG T1) bladder cancer at initial transurethral resection of the bladder (TURB) and no residual tumor at second TURB.</div></div><div><h3>Methods</h3><div>After initial evaluation, participants diagnosed with HG T1 bladder cancer who had undergone complete eradication of visible tumors underwent a second TURB. Those with specimens showing T0 were randomized to either AS or to intravesical BCG for 8 wk without maintenance therapy. The primary endpoint was invasive relapse–free survival (iRFS).</div></div><div><h3>Key findings and limitations</h3><div>In total, 513 participants were enrolled in the initial evaluation. After second TURB, 263 participants were enrolled and randomized. AS was noninferior to BCG in terms of iRFS (hazard ratio 0.69, 90% confidence interval 0.44–1.08; <em>p</em> = 0.001). Rates of adverse events were 50% and 90% for any grade, and in 3.1% and 3.8% for grade ≥3 events in the AS and BCG arms, respectively. The protocol treatment in the control arm was not the current standard.</div></div><div><h3>Conclusions and clinical implications</h3><div>In this highly selected patient population, AS was noninferior to eight-dose intravesical BCG induction therapy in terms of iRFS for T1 disease or deeper intravesical and/or extravesical recurrence. The safety profile of AS was better than that of BCG. These findings indicate that AS represents a potentially viable therapeutic strategy for selected patients with HG T1 bladder cancer for whom second TURB demonstrates the absence of residual disease.</div></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Pages 437-445"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146014329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Rebecca Voelker. What Is Prostate Cancer? JAMA. In press. https://doi.org/10.1001/jama.2025.10177","authors":"Giorgio Gandaglia ,&nbsp;Alberto Briganti ,&nbsp;James W. Catto ,&nbsp;Philip Cornford ,&nbsp;Neil E. Fleshner ,&nbsp;Markus Graefen ,&nbsp;Mani Menon ,&nbsp;Francesco Montorsi","doi":"10.1016/j.eururo.2025.09.4181","DOIUrl":"10.1016/j.eururo.2025.09.4181","url":null,"abstract":"","PeriodicalId":12223,"journal":{"name":"European urology","volume":"89 5","pages":"Page e121"},"PeriodicalIF":25.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}